Lundbeck to present bexicaserin mechanistic insights at European Epilepsy Congress

Lundbeck will present new preclinical data on its drug candidate bexicaserin at the upcoming European Epilepsy Congress.

The presented findings provide mechanistic insight into bexicaserin's dual mode of action. Preclinical studies suggest the drug increases inhibitory neuronal activity while decreasing excitatory activity. This dual action indicates a broader antiseizure potential in preclinical models, encompassing focal, generalized motor, and absence seizures across different etiologies.

Bexicaserin is currently being evaluated in the global Phase III DEEp Program, which focuses on treating seizures associated with developmental and epileptic encephalopathies (DEEs). Lundbeck will present both clinical and preclinical research from the broader development program at the congress.

The development of new epilepsy treatments is an active area of research. Drugs like bexicaserin are being investigated to offer alternatives for patients whose seizures are not adequately controlled by existing therapies. DEE conditions are particularly challenging and require novel therapeutic approaches.

Lundbeck's presentation at the congress offers experts an opportunity to delve into bexicaserin's potential as a new treatment for epilepsy and discuss its ongoing development.